Abstract
Clindamycin was first synthesized in 1966. It is a chemical derivative of lincomycin with activity against aerobic gram-positive and gram-negative bacteria. The side effects include diarrhea, pseudomembranous colitis, metallic taste in the mouth, transient elevation of transaminases, granulocytopenia, thrombocytopenia, and rash. The incidence of maculopapular rashes has been reported to be approximately 10%. Leukocytoclastic angitis or vasculitis induced by clindamycin has been reported (Lambert et al., Cutis 30:615–619, 1982) and this is a very serious complication in patients with peripheral arterial vascular diseases which may leads to severe and deep necrotizing vasculitis. We report two cases of necrotizing vasculitis due to clindamycin which was used for the treatment of chronic wounds in patients suffering of peripheral vascular disease.
References
Lambert WC, Kolber LR, Proper SA (1982) Leukocytoclastic angiitis induced by clindamycin. Cutis 30:615–619
Fulghum DD, Catalano PM (1973) Steven–Johnson syndrome from clindamycin. JAMA 223:318–319
Vidal C, Iglesias A, Saez A et al (1991) Hypersensitivity to clindamycin. DICP 25:317 (Letter)
Acknowledgment
The authors acknowledge the Department of Pathology for the recognition of leukocytoclastic vasculitis and Dhamar University in Yemen for the support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al-Jamali, J., Felmerer, G., Kasem, A. et al. Clindamycin vasculitis in patients with peripheral arterial vascular disease. Eur J Plast Surg 32, 267–269 (2009). https://doi.org/10.1007/s00238-009-0343-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00238-009-0343-6